Concert Pharmaceuticals wants to use deuterium chemistry to conduct a symphony of drugs. The company's process lets it substitute deuterium (also called heavy hydrogen) for hydrogen in a chemical compound thereby making the compound more stable without changing its other properties. It also believes this process will lead to shorter time from discovery to trial for certain drugs. Concert has a handful of clinical-stage candidates in various stages of the approval process, including treatments for spasticity, kidney disease, and neurologic disorders. It collaborates with Avanir, Celgene, and Jazz Pharmaceuticals on development. Concert began its song in 2006 and took the show public in 2014.